Pharma Journalist -

Rigel Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with…
Read More...

Lannett Company announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules…
Read More...

Boehringer Ingelheim announced results from the pivotal Phase III VOLTAIRE-RA study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA have similar efficacy,…
Read More...

Johnson & Johnson announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash. The acquisition was completed through…
Read More...

Baxter International announced an agreement with Dorizoe Lifesciences Limited (Dorizoe), a full-service global contract research and development (R&D) organization, that will…
Read More...

Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients. The SAPHIR study is the first clinical trial…
Read More...

Pfizer and Basilea Pharmaceutica announced that they have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe to CRESEMBA…
Read More...

Generon Corporation announced the initiation of a clinical trial for A-337, a CD3-activating bi-specific antibody targeting EpCAM, in Australia. This is a “Phase I, Open-label,…
Read More...

LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that…
Read More...

SGS announced that it has significantly increased its capabilities to undertake extractables and leachables (E&L) testing at its Shanghai, China, laboratory. Its investment…
Read More...